| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_44a6cf3a4261637e5938bbeb0e6baf25 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1278 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-40 |
| filingDate |
2005-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2008-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ee9b9d184286b0641f9a9a1827c0b68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa60b0cfb88032180d5deb0347ed7097
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b657d00caa81f7c7d449fe47c1f6b447
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f555663eadc734aadc9d29c01a0b8935
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57b3e3f3ce1383db350a6b4d5610faaa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ffdaeedae57dbc9977ea0a86c0c26c50 |
| publicationDate |
2008-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7438909-B2 |
| titleOfInvention |
Immunization and treatment methods for anthrax |
| abstract |
A highly efficient method for generating human antibodies using recall technology is provided. In one aspect, human antibodies which are specific to the anthrax toxin are provided. In one aspect, human peripheral blood cells that have been pre-exposed to anthrax toxin are used in the SCID mouse model. This method results in high human antibody titers which are primarily of the IgG isotype and which contain antibodies of high specificity and affinity to desired antigens. The antibodies generated by this method can be used therapeutically and prophylactically for preventing or treating mammals exposed to anthrax. Thus, in one embodiment, a prophylactic or therapeutic agent used to counter the effects of anthrax toxin, released as a mechanism of bioterrorism, is provided. In one embodiment, a formulation and method for preventing and/or treating anthrax infection comprising a binding agent that prevents the assembly of the PA63 heptamer is also provided. Methods for diagnosis and methods to determine anthrax contamination are also described. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010063099-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10357559-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011229507-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9017681-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7906119-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9095578-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007202117-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010168203-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8778359-B2 |
| priorityDate |
2003-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |